Nulojix (belatacept) - BMS
Flow cytometry immune profiling provides early detection of rejection of islet xenotransplants (TTS 2026) - Sep 17, 2026 - Pres time: Sep 22, 2026; 04:37 PM - 04:44 PM; Location: Room C4.1; 385; "All recipients received anti-CD2 induction and maintenance with anti-CD154 and Belatacept... This study demonstrates reliable flow cytometry for assessing immune status in xeno-islet recipients and the potential to predict and prevent early graft rejection." 
Diabetes • Inflammation • Metabolic Disorders • Transplant Rejection • Transplantation • Type 1 Diabetes Mellitus • CD40LG • CD8
https://app.tts2026.org/program_view/presentation/480
 
Thanh Le1; Erin Fuller1; Lauren Joo1; Evelyn Salvaris2; Adwin Thomas1; Francesco Ierino3; Mark Nottle4; Peter Cowan2,3; Wayne Hawthorne1,5
 
Sep 17, 2026
 
Prev Next